GSK 626616 New
Chemical Name: (5Z)-2-[(2,6-Dichlorophenyl)amino]-5-(6-quinoxalinylmethylene)-4(5H)-thiazolone
Biological ActivityPotent and selective DYRK inhibitor (IC50 = 0.7 nM for DYRK3, similar potency for DYRK1 and 2). Exhibits ~20-fold selectivity over casein kinase 2 and negligible activity against a panel of 451 kinases screened. Enhances number of CFU-E stimulated by Epo from human marrow. Increases hemoglobin levels in anemic mice. Orally bioavailable.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling.
Wippich et al.
Kinase-controlled phase transition of membraneless organelles in mitosis.
Rai et al.
GSK626616: A DYRK3 inhibitor as a potential new therapy for the treatment of anemia.
Erickson-Miller et al.
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for GSK 626616
There are currently no reviews for this product. Be the first to review GSK 626616 and earn rewards!
Have you used GSK 626616?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image